SCHEDULE 13G/A: Janus Henderson Group Discloses 10.1% Stake in Madrigal Pharmaceuticals

Janus Henderson Group plc has filed an amended Schedule 13G, revealing a 10.1% beneficial ownership stake in Madrigal Pharmaceuticals, Inc. as of December 31, 2024.

Summary

• Janus Henderson Group plc reported beneficial ownership of 2,195,758 shares of Common Stock in Madrigal Pharmaceuticals, Inc.
• This represents a 10.1% stake in the class of securities.
• The filing indicates that Janus Henderson Group plc, through its indirect subsidiaries JHIUS, JHIUKL, and JHIAIFML, holds shared voting and shared dispositive power over all beneficially owned shares.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not convey positive or negative sentiment regarding the issuer's performance or prospects. It simply reports an institutional stake.

Future Outlook

NA

Industry Context

This Schedule 13G filing indicates a significant institutional investment by Janus Henderson Group, a global asset manager, in Madrigal Pharmaceuticals, a company in the pharmaceutical sector. Such filings provide transparency on major ownership stakes, which can be a signal of institutional confidence or strategic positioning within the industry.

Stakeholder Impact

• Provides transparency to shareholders and the market regarding significant institutional ownership in Madrigal Pharmaceuticals.
• Indicates a substantial investment by Janus Henderson Group, potentially signaling confidence in Madrigal Pharmaceuticals' long-term prospects to other investors.

Key Dates

Keywords

Janus Henderson Group, Madrigal Pharmaceuticals, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Pharmaceuticals, Investment Adviser, Holding Company